High-grade B-cell lymphoma Burkitt-like lymphoma recurrent is an aggressive form of cancer that affects the body’s immune system. When this disease returns after initial treatment, it presents significant challenges for both patients and medical teams, requiring specialized approaches to manage this fast-growing condition.
Understanding High-Grade B-Cell Lymphoma with Burkitt-Like Features
High-grade B-cell lymphoma with Burkitt-like features represents a particularly aggressive type of cancer that develops from B lymphocytes, which are specialized white blood cells that help your body fight infections. These cancers grow rapidly and can spread quickly through the body’s lymphatic system, a network of organs, vessels, and tissues that normally helps protect against disease. When this condition is described as “recurrent,” it means the cancer has come back after previously responding to treatment.[1]
This type of lymphoma shares characteristics with both diffuse large B-cell lymphoma and Burkitt lymphoma, making it challenging to classify and treat. The World Health Organization designated high-grade B-cell lymphoma as its own category in 2016, recognizing that it differs in important ways from other B-cell cancers. One defining feature is the presence of rearrangements in specific genes, particularly the MYC gene, along with either the BCL2 gene or BCL6 gene. These genetic changes cause normal B cells to become cancer cells that multiply uncontrollably.[5]
About five percent of diffuse large B-cell lymphomas have these dual gene rearrangements and are therefore classified as high-grade B-cell lymphoma. Additionally, between 32 and 78 percent of Burkitt lymphomas show similar genetic patterns. Molecular testing that allows doctors to examine chromosomes under a microscope helps confirm the diagnosis of this condition. Accurate diagnosis is absolutely critical because high-grade B-cell lymphoma and regular Burkitt lymphoma require different treatment approaches.[5]
How Common Is This Condition?
Burkitt lymphoma itself is quite rare, accounting for approximately one percent of all non-Hodgkin lymphoma cases. It is one of the most aggressive cancers known, with a rapid growth pattern that is uniformly fatal if left untreated. The sporadic form of Burkitt lymphoma, which is the type most commonly seen in Western countries like the United States and Europe, accounts for less than one percent of B-cell non-Hodgkin lymphomas in adults. However, it represents about 30 percent of all childhood lymphomas, making it more common in younger patients.[8]
B-cell lymphomas as a group make up about 85 percent of all non-Hodgkin lymphomas. The American Cancer Society estimates that approximately 80,600 people will receive a non-Hodgkin lymphoma diagnosis in 2024, though only a small fraction of these will be high-grade B-cell lymphoma with Burkitt-like features.[7]
In the United Kingdom, only around 250 people are diagnosed with Burkitt lymphoma each year. The condition affects males significantly more often than females, with three to four times more men developing the disease. This gender difference is consistent across different geographical regions and age groups.[4]
What Causes This Disease?
The development of high-grade B-cell lymphoma and Burkitt lymphoma involves complex genetic changes that transform normal B lymphocytes into cancer cells. The most critical change involves chromosomal translocations, which occur when parts of genes switch places within chromosomes. The hallmark of these conditions is a translocation involving the MYC gene, a proto-oncogene that normally helps control cell growth. When MYC moves to a new location on a chromosome, it becomes overactive, causing cells to multiply without proper control.[1]
Infection with Epstein-Barr virus (EBV) is a known risk factor for Burkitt lymphoma. EBV is a common virus that often causes symptoms similar to a cold or infectious mononucleosis. While nearly all endemic cases of Burkitt lymphoma found in Africa are associated with EBV infection, only a small proportion of sporadic cases in Western countries show evidence of this viral infection. In endemic Burkitt lymphoma, a specific EBV protein called EBNA1 is expressed in the cancer cells.[1]
The virus contributes to cancer development through several mechanisms. When EBV infects B cells, certain viral genes are deleted, leading to the expression of other genes called EBNA3A-C. Tumor cells derived from these infected cells become resistant to apoptosis, which is the normal process of programmed cell death that prevents damaged cells from becoming cancerous. This gives the cancer cells a survival advantage, allowing them to continue growing and dividing when they should die.[1]
Who Is at Higher Risk?
Several factors increase a person’s likelihood of developing high-grade B-cell lymphoma or Burkitt lymphoma. Human immunodeficiency virus (HIV) infection is a significant risk factor, particularly for the immunodeficiency-related variant of Burkitt lymphoma. People living with HIV have weakened immune systems that cannot effectively control the growth of abnormal cells. The immunodeficiency-related form is most common in people with HIV/AIDS, though it can also occur in patients with inherited immune deficiencies.[3]
Organ transplant recipients who take immunosuppressive medications to prevent organ rejection are also at increased risk. These medications deliberately weaken the immune system to stop it from attacking the transplanted organ, but this also reduces the body’s ability to recognize and destroy cancer cells. In immune-compromised individuals, EBV-driven B-cell proliferation can lead to the accumulation of genetic mutations, particularly the MYC translocation, which drives uncontrolled B-cell growth and ultimately results in lymphoma development.[1]
Age plays a role in disease presentation, though in different ways depending on the subtype. The endemic form, common in Africa, primarily affects children, especially boys. The sporadic form seen in the United States and Western Europe most frequently occurs in young adults. Children in sub-Saharan Africa face the highest risk for endemic Burkitt lymphoma, where it is the most common childhood cancer.[1]
Geographic location influences risk through exposure to specific infectious agents. In areas where malaria is constantly present, the combination of chronic malaria infection and Epstein-Barr virus infection significantly increases the risk of developing endemic Burkitt lymphoma. This explains why the incidence rate in equatorial Africa and New Guinea is about 50 times higher than in the United States.[3]
Recognizing the Symptoms
The symptoms of high-grade B-cell lymphoma and Burkitt lymphoma often appear suddenly and progress quickly because these are fast-growing cancers. The signs vary depending on where the lymphoma develops in the body. One of the most common symptoms is the rapid growth of a tumor or mass, often in the abdomen. Many patients experience abdominal pain or swelling as the tumor grows and puts pressure on surrounding organs and tissues.[3]
Swollen lymph nodes are another frequent symptom. These may appear in the neck, armpit, or groin as painless lumps under the skin. Unlike lymph nodes that swell during a simple infection, these typically do not become tender or painful, and they do not shrink on their own. The sporadic form of Burkitt lymphoma most commonly presents with an abdominal tumor, while the endemic form often causes growths in the jaw, facial bones, or the area around the eyes.[3]
Digestive system symptoms are common when the disease affects the intestines. Patients may experience nausea, vomiting, or changes in bowel habits. Some people develop difficulty eating or feel full very quickly during meals. These symptoms occur because the tumor interferes with normal digestion and the movement of food through the gastrointestinal tract.[3]
General symptoms that affect the whole body include unexplained weight loss, which occurs without trying to lose weight or changing eating habits. Many patients develop fever that comes and goes without an obvious cause like an infection. Night sweats are particularly characteristic, sometimes severe enough to soak through nightclothes and bedding. Persistent fatigue or weakness makes it difficult to carry out normal daily activities, and decreased appetite often accompanies these other symptoms.[3]
When Burkitt lymphoma spreads to the central nervous system, additional symptoms may develop. These can include headaches, confusion, difficulty with movement or coordination, or changes in sensation. The disease may also affect the bone marrow, kidneys, ovaries, or other organs, causing symptoms specific to those areas of the body. Because these cancers can advance so rapidly, early detection and prompt medical evaluation are absolutely critical for the best possible outcomes.[3]
Can This Disease Be Prevented?
Complete prevention of high-grade B-cell lymphoma and Burkitt lymphoma is not currently possible because many of the genetic changes that cause these diseases occur unpredictably. However, certain measures can reduce risk, particularly for people with known risk factors. For individuals infected with HIV, maintaining good control of the virus through antiretroviral therapy helps keep the immune system functioning better, which may reduce the risk of developing lymphoma. Regular medical care and monitoring are essential for people living with HIV.[3]
In areas where malaria is endemic, malaria prevention and treatment programs may indirectly help reduce the risk of endemic Burkitt lymphoma. Using insecticide-treated bed nets, taking antimalarial medications when appropriate, and seeking prompt treatment for malaria infections are all important public health measures. While these steps do not directly prevent lymphoma, they address one of the environmental factors associated with the endemic form of the disease.[1]
For organ transplant recipients, the risk of lymphoma must be balanced against the need for immunosuppressive medications. Healthcare providers carefully monitor these patients and adjust medication doses to provide the minimum immunosuppression needed to prevent organ rejection. Regular screening and vigilance for signs of lymphoma allow for earlier detection if the disease does develop.[3]
Because accurate diagnosis is critical for proper treatment, seeking evaluation by healthcare professionals with expertise in lymphoma is strongly recommended when symptoms appear. Early detection when the disease is still localized may improve treatment outcomes, though this can be challenging given how quickly these cancers grow and spread.[3]
What Happens in the Body During This Disease?
Understanding what happens inside the body when high-grade B-cell lymphoma develops helps explain why this disease is so aggressive. Normal B lymphocytes are part of the adaptive immune system. They circulate through the blood and lymphatic system, and when they encounter a foreign invader like a bacterium or virus, they can transform into plasma cells that produce antibodies to fight the infection. This is a carefully controlled process that includes built-in checkpoints to prevent excessive cell growth.[1]
In high-grade B-cell lymphoma and Burkitt lymphoma, genetic changes disrupt these normal control mechanisms. The MYC gene normally produces a protein that regulates cell division and growth. When chromosomal translocation places MYC next to highly active gene regions, the MYC protein is produced in excessive amounts. This drives continuous, uncontrolled cell division. The cells lose their ability to mature properly into functional B lymphocytes and instead remain in an immature, rapidly dividing state.[8]
Additional genetic changes involving BCL2 or BCL6 genes compound the problem. The BCL2 gene normally helps determine when a cell should undergo apoptosis. When both MYC and BCL2 are rearranged (creating what doctors call “double-hit” lymphoma), the cancer cells both divide rapidly and resist normal cell death signals. This combination creates particularly aggressive disease that is difficult to control with standard treatments.[5]
Under a microscope, Burkitt lymphoma shows characteristic features. The cancer consists of monomorphic medium-sized B cells with specific appearance characteristics: basophilic cytoplasm (which means the cell interior stains blue), numerous mitotic figures showing active cell division, rounded nuclei with finely clumped chromatin, and extensive apoptosis. Specialized cells called tingible body macrophages create a distinctive “starry sky” appearance as they clean up dying tumor cells.[8]
The rapid cell division means these tumors have extremely high growth rates. Burkitt lymphoma cells can double in number in just 24 to 48 hours, which is among the fastest growth rates of any human cancer. This explains why symptoms often appear suddenly and progress so quickly, and why even short delays in treatment can allow significant disease progression.[8]
Because the cancer cells are immature B lymphocytes, they can grow anywhere that normal B cells travel. This includes lymph nodes throughout the body, the bone marrow where blood cells are made, the spleen, and many other organs. The disease has a particular tendency to affect the jaw and facial bones (in endemic form), the abdomen and intestines (in sporadic form), and can spread to the central nervous system, which includes the brain and spinal cord.[2]
The Challenge of Recurrent Disease
Despite excellent results with initial treatment, particularly in children where cure rates can exceed 90 percent, recurrent Burkitt lymphoma and high-grade B-cell lymphoma remain significant challenges. When the disease comes back after initial treatment, the prognosis becomes much more difficult. The outlook for recurrent disease is very poor, with survival rates ranging from less than 10 percent to 30-40 percent, and longer survival typically occurs only in patients who undergo hematopoietic stem cell transplantation.[6]
The limited data available on treating recurrent disease makes it difficult to determine the best treatment approach. Most published reports describe small groups of patients with varying characteristics who received different salvage treatments, so drawing definitive conclusions about optimal therapy is currently impossible. This lack of clear guidance reflects both the rarity of these conditions and the challenge of studying diseases that progress so rapidly.[6]
Cure rates for initial treatment differ significantly between age groups. In children, intensive chemotherapy can cure more than 90 percent of patients. In adults, cure rates reach approximately 70 percent with modern treatment approaches. However, when disease recurs or proves resistant to initial treatment, these favorable statistics no longer apply. Only a small fraction of patients with refractory disease achieve long-term survival.[6]
In high-income countries, where intensive treatment regimens and sophisticated supportive care are available, outcomes are dramatically better than in resource-limited settings. Although Burkitt lymphoma represents only a small minority of newly diagnosed non-Hodgkin lymphomas in Western countries, it is the most common childhood cancer in sub-Saharan Africa. In these areas, prognosis remains poor and has been virtually unchanged over time, highlighting how access to advanced medical care affects outcomes.[6]
Several patient groups require therapy optimization. Older patients or those with multiple medical problems are often unable to tolerate the highly intensive chemotherapy regimens used in younger, healthier patients. These individuals need alternative approaches that balance effectiveness against tolerability. Researchers continue to investigate new treatment strategies specifically designed for patients who cannot receive standard intensive therapy.[6]
New insights into the cell biology of these diseases have led to the development of drugs directed at specific molecular targets. These targeted therapies are currently being tested in clinical trials and may offer hope for patients with recurrent or resistant disease. However, these treatments are still experimental, and their role in managing recurrent disease is not yet fully established.[6]